Outcomes of the EVO ICL Using a Customized Non-horizontal or Horizontal Implanting Orientation Based on UBM Measurement: A Pilot Study

基于UBM测量结果的EVO ICL植入术采用定制的非水平或水平植入方向的疗效:一项初步研究

阅读:1

Abstract

INTRODUCTION: To evaluate the short-term safety and efficacy of the EVO implantable collamer lens (ICL) using a customized implanting orientation design based on ultrasound biomicroscope (UBM) measurement. METHODS: The prospective case series included 310 eyes of 158 patients treated with ICL. To achieve an optimal vault, an ICL of specific size was chosen and implanted in a customized orientation according to assessment of sulcus-to-sulcus (STS) diameters, distance between STS plane and crystalline lens (STSL), the morphology of ciliary sulcus (MCS), anterior chamber depth (ACD), and white-to-white (WTW). With the new design, there were 138 eyes with a non-horizontal orientation and 172 eyes with a horizontal orientation of the ICL. Refractive and ICL vault statuses were followed up for 1 day and 1 month postoperatively. RESULTS: The safety index at 1 month was 1.34 ± 0.17 for the non-horizontally implanted group and 1.33 ± 0.16 for the horizontally implanted group; the efficacy index was 1.21 ± 0.18 for the non-horizontally implanted group and 1.18 ± 0.16 for the horizontally implanted group. All eyes achieved an uncorrected distance visual acuity of 0.10 logMAR or better. No significant difference in endothelial cell density was observed between the preoperative value (2792.6 ± 247.6 cells/mm(2)) and value at 1 month postoperatively (2744.2 ± 243.3 cells/mm(2)), and no cataract or anterior subcapsular opacification was observed. Ideal vault (250-750 μm) was achieved in 84% of eyes (260/310). CONCLUSION: The customized ICL design of implanting orientation based on UBM measurement provides good safety, efficacy, and vault predictability.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。